Основные проблемы старения и ограниченные возможности заместительной гормональной терапии у женщин
Основные проблемы старения и ограниченные возможности заместительной гормональной терапии у женщин
Шишкова В.Н. Основные проблемы старения и ограниченные возможности заместительной гормональной терапии у женщин. Consilium Medicum. 2016; 18 (9): 151–158. DOI: 10.26442/2075-1753_2016.9.151-158
________________________________________________
Shishkova V.N. The main problems of aging and the limited capacity of hormone replacement therapy in women. Consilium Medicum. 2016; 18 (9): 151–158. DOI: 10.26442/2075-1753_2016.9.151-158
Основные проблемы старения и ограниченные возможности заместительной гормональной терапии у женщин
Шишкова В.Н. Основные проблемы старения и ограниченные возможности заместительной гормональной терапии у женщин. Consilium Medicum. 2016; 18 (9): 151–158. DOI: 10.26442/2075-1753_2016.9.151-158
________________________________________________
Shishkova V.N. The main problems of aging and the limited capacity of hormone replacement therapy in women. Consilium Medicum. 2016; 18 (9): 151–158. DOI: 10.26442/2075-1753_2016.9.151-158
В статье рассматриваются вопросы старения в целом и особенности проявления старения у женщин, в частности проявлений менопаузы. Представлены современные взгляды на терапию основных возрастассоциированных заболеваний у женщин в постменопаузе, в том числе когнитивных нарушений. Показана возможность эффективного применения препарата Церебролизин у женщин в постменопаузе.
The article deals with aging in general and the effects of aging in women, particularly menopausal symptoms. Presents modern views on the basic therapy of age-related diseases in postmenopausal women, including cognitive impairment. The possibility of effective use of the drug in women Cerebrolysin.
1. World Population Ageing. United Nations publication 2009; Sales No. E.10.XIII.5
2. Практические рекомендации. Ведение женщин в пери- и постменопаузе. Москва 2010. Под ред. В.П.Сметник, Л.М.Ильина. Ярославль: Литера, 2010; с. 222. / Prakticheskie rekomendatsii. Vedenie zhenshchin v peri- i postmenopauze. Moskva 2010. Pod red. V.P.Smetnik, L.M.Il'ina. Iaroslavl': Litera, 2010; s. 222. [in Russian]
3. Чазова И.Е., Сметник В.П., Балан В.Е. и др. Ведение женщин с сердечно-сосудистым риском в пери- и постменопаузе: консенсус российских кардиологов и гинекологов. Проблемы репродукции. 2008; 5: 79–87. / Chazova I.E., Smetnik V.P., Balan V.E. i dr. Vedenie zhenshchin s serdechno-sosudistym riskom v peri- i postmenopauze: konsensus rossiiskikh kardiologov i ginekologov. Problemy reproduktsii. 2008; 5: 79–87. [in Russian]
4. Salomon JA, Wang H, Freeman MK et al. Healthy life expectancy for 187 countries, 1990–2010: a systematic analysis for the Global Burden Disease Study 2010. The Lancet 2012; 380: 2144–62.
5. Masson M, Siniawski D, Krauss J, Cagide A. Clinical Applicability of the Framingham 30-Year Risk Score. Usefulness in Cardiovascular Risk Stratification and the Diagnosis of Carotid Atherosclerotic Plaqu. Rev Esp Cardiol 2011; 64 (4): 305–11.
6. Sturdee DW, Pines A on behalf of the International Menopause Society Writing Group. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 2011; 14: 302–20.
7. Physicians’ perception of guideline-recommended low-density lipoprotein target values: characteristics of misclassified patients). European Heart J 2010. doi: 10.1093/eurheartj/ehq026
8. Brown S, Rosen CJ. Osteoporosis. Med Clin North Am 2003; 87: 1039–63.
9. Roussow JE, Anderson GL, Prentice RL et al. Writing group for the women\'s health initiative investigators. Risks and benefits of estrogen + progestin in healthy postmenopausal women. JAMA 2002; 288: 321–33.
10. Остеопороз. Диагностика, профилактика и лечение. Клинические рекомендации. Под ред. Л.И.Беневоленской, О.М.Лесняк. М.: ГЭОТАР-Медиа, 2010. / Osteoporoz. Diagnostika, profilaktika i lechenie. Klinicheskie rekomendatsii. Pod red. L.I.Benevolenskoi, O.M.Lesniak. M.: GEOTAR-Media, 2010. [in Russian]
11. Birns J, Morris R, Donaldson N, Kalra L. The effects of blood pressure reduction on cognitive function: a review of effects based on pooled data from clinical trials. J Hypertens 2006; 24: 1907–14.
12. Birns J, Kalra L. Cognitive function and hypertension. Human Hypertension 2009; 23: 86–96.
13. O’Brien JT, Erkinjuntti T, Reisberg B et al. Vascular cognitive impairment. Lancet Neurology 2003; 2: 89–98.
14. Штульман Д.Р., Левин О.С. Неврология. Справочник практического врача. М.: Медпресс-информ, 2008. / Shtul'man D.R., Levin O.S. Nevrologiia. Spravochnik prakticheskogo vracha. M.: Medpress-inform, 2008. [in Russian]
15. Trojano L, Incalzi RA, Acaforo D et al. Cognitive Impairment: a key feature of congestive heart failure in the elderly. J Neurol 2003; 250: 1456–63.
16. Jefferson A, Benjamin E. Cardiovascular disease, cognitive decline and dementia. Vascular cognitive impairment in clinical practice. Eds. L.Wahlung, T.Erkinjuntti, S.Gauthier. Cambridge, 2009; p. 166–77.
17. Cacciatore F, Abete P, Ferrara N et al. Congestive heartfailure and cognitive impairment in an older population. Am Geriatr Soc 1998; 46: 1343–8.
18. Pullicino PM, Hart J. Cognitive Impairment in congestive heart failure. Neurology 2001; 57: 1945–6.
19. Gorkin L, Norvell NK, Rosen RC et al. Assessment of quality of life as observed from the baseline data of the studies of left ventricular dysfunction (SOLVD) trial quality of life substudy. Am J Cardiol 1993; 71: 1069–73.
20. Georgiadis D, Sievert M, Cencetti S et al. Cerebrovascular reactivity is impaired in patients with cardiac failure. Eur Heart J 2000; 21: 407–13.
21. Захаров В.В., Яхно Н.Н. Когнитивные расстройства в пожилом и старческом возрасте. Методическое пособие для врачей. М., 2005. / Zakharov V.V., Iakhno N.N. Kognitivnye rasstroistva v pozhilom i starcheskom vozraste. Metodicheskoe posobie dlia vrachei. M., 2005. [in Russian]
22. Суслина З.А., Варакин Ю.Я., Верещагин Н.В. Сосудистые заболевания головного мозга. Эпидемиология. Основы профилактики. М.: МЕДпресс-информ, 2009. / Suslina Z.A., Varakin Iu.Ia., Vereshchagin N.V. Sosudistye zabolevaniia golovnogo mozga. Epidemiologiia. Osnovy profilaktiki. M.: MEDpress-inform, 2009. [in Russian]
23. Дамулин И.В. Болезнь Альцгеймера и сосудистая деменция. Под ред. Н.Н.Яхно. М., 2002; с. 85. / Damulin I.V. Bolezn' Al'tsgeimera i sosudistaia dementsiia. Pod red. N.N.Iakhno. M., 2002; s. 85. [in Russian]
24. Инсульт. Руководство. Под ред. Л.В.Стаховской, С.В.Котова. М.: МИА, 2014. / Insul't. Rukovodstvo. Pod red. L.V.Stakhovskoi, S.V.Kotova. M.: MIA, 2014. [in Russian]
25. Гомазков О.А. Нейротрофические и ростовые факторы мозга: регуляторная специфика и терапевтический потенциал. Успехи физиолог. наук. 2005; 36 (2): 1–25. / Gomazkov O.A. Neirotroficheskie i rostovye faktory mozga: reguliatornaia spetsifika i terapevticheskii potentsial. Uspekhi fiziolog. nauk. 2005; 36 (2): 1–25. [in Russian]
26. Гусев Е.И., Боголепова А.Н. Когнитивные нарушения при цереброваскулярных заболеваниях. М.: МЕДпреcс-информ, 2013. / Gusev E.I., Bogolepova A.N. Kognitivnye narusheniia pri tserebrovaskuliarnykh zabolevaniiakh. M.: MEDprecs-inform, 2013. [in Russian]
27. Гусев Е.И., Скворцова В.И. Ишемия головного мозга. М.: Медицина, 2001. / Gusev E.I., Skvortsova V.I. Ishemiia golovnogo mozga. M.: Meditsina, 2001. [in Russian]
28. Heiss WD et al. Cerebrolysin in Patients with acute Ischemic Stroke in Asia results of a double-blind, placebo controlled randomized trial. Stroke 2012; 43 (3): 631–6.
29. Гусев Е.И., Гехт А.Б. и др. Клинические и фармакоэкономические особенности применения Церебролизина в восстановительном лечении ишемического инсульта. Журн. неврологии и психиатрии им. С.С.Корсакова. 2007; 107 (10): 26–33. / Gusev E.I., Gekht A.B. i dr. Klinicheskie i farmakoekonomicheskie osobennosti primeneniia Tserebrolizina v vosstanovitel'nom lechenii ishemicheskogo insul'ta. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2007; 107 (10): 26–33. [in Russian]
30. Guekht AB, Moessler H, Novak PH, Gusev EI. Cerebrolysin in Vascular Dementia: Improvement of Clinical Outcome in a Randomized, Double-Blind, Placebo-Controlled Multicenter Trial. J Stroke Cerebrovasc Dis 2010; p. 1–9. [in Russian]
31. Chen N et al. Cerebrolysin for vascular dementia (Review), The Cochrane Collaboration, 2013.
32. Wei Z, He Q, Wang B, Chen H. Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer’s disease, J Neural Transm 2007; 114 (5 Suppl.): 629–34.
33. Alvarez XA, Sampedro C, Figueroa J et al. Reductions in qEEG slowing over one year and after treatment with Cerebrolysin in patients with moderate-sever traumatic brain injury. J Neural Transm 2008; 115 (Suppl.): 683–92.
34. Wang M et al. The effect observation of head injury treated with Cerebrolysin. J Xi’an Med University 1998; 19 (4).
35. Калын Я.Б., Сафарова Т.П. и др. Сравнительная эффективность и безопасность антидепрессивной моно- и мультимодальной терапии у пожилых больных депрессией. Журн. неврологии и психиатрии им. С.С.Корсакова.2014; 114 (6): 20–9. / Kalyn Ia.B., Safarova T.P. i dr. Sravnitel'naia effektivnost' i bezopasnost' antidepressivnoi mono- i mul'timodal'noi terapii u pozhilykh bol'nykh depressiei. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova.2014; 114 (6): 20–9. [in Russian]
36. Chen H et al. Trophic factors counteract elevated FGF-2-induced inhibition of adult neurogenesis. Neurobiol Aging 2007; 28 (8): 1148–62.
37. Громова О.А., Торшин И.Ю., Гоголева И.В. Механизмы нейротрофического и нейропротекторного действия препарата церебролизин при ишемии головного мозга. Журн. неврологии и психиатрии им. С.С.Корсакова. 2014; 3 (Вып. 2): 43–50. / Gromova O.A., Torshin I.Iu., Gogoleva I.V. Mekhanizmy neirotroficheskogo i neiroprotektornogo deistviia preparata tserebrolizin pri ishemii golovnogo mozga. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2014; 3 (Vyp. 2): 43–50. [in Russian]
38. Громова О.А., Третьяков В.Е., Мошковский С.А. и др. Олигипептидная мембранная фракция церебролизина (перевод). Журн. неврологии и психиатрии им. С.С.Корсакова. 2006; 106 (7): 68–70. / Gromova O.A., Tret'iakov V.E., Moshkovskii S.A. i dr. Oligipeptidnaia membrannaia fraktsiia tserebrolizina (perevod). Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2006; 106 (7): 68–70. [in Russian]
39. Громова О.А. и др. Молекулярные механизмы воздействия аминокислот в составе Церебролизина на нейротрансмиссию. Нейротрофические и нейропротективные эффекты аминокислот. Трудный пациент. 2010; 8 (4): 25–31. / Gromova O.A. i dr. Molekuliarnye mekhanizmy vozdeistviia aminokislot v sostave Tserebrolizina na neirotransmissiiu. Neirotroficheskie i neiroprotektivnye effekty aminokislot. Trudnyi patsient. 2010; 8 (4): 25–31. [in Russian]
40. Громова О.А., Кудрин А.В. Новые грани молекулярной фармакологии нейротрофиков природного происхождения. Микроэлементы как компонент нейропротекторных лигандов (обзор). Междунар. мед. журн. 2001; 4: 441–5. / Gromova O.A., Kudrin A.V. Novye grani molekuliarnoi farmakologii neirotrofikov prirodnogo proiskhozhdeniia. Mikroelementy kak komponent neiroprotektornykh ligandov (obzor). Mezhdunar. med. zhurn. 2001; 4: 441–5. [in Russian]
41. Громова О.А., Красных Л.М., Гусев Е.И., Никонов А.А., Витаминная активность церебролизина. Журн. неврологии и психиатрии им. С.С.Корсакова. 2005; 5: 59–61. / Gromova O.A., Krasnykh L.M., Gusev E.I., Nikonov A.A., Vitaminnaia aktivnost' tserebrolizina. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2005; 5: 59–61. [in Russian]
42. Muresanu DF, Buzoianu A, Florian SI, von Wild T. Towards a roadmap in brain protection and recovery. J Cell Mol Med 2012; 16 (12): 2861–71.
43. Masliah E, Díez-Tejedor E. The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs Today (Barc) 2012; 48 (Suppl. A): 3–24. doi: 10.1358/dot.2012.48(Suppl.A).1739716.
44. Ubhi K, Rockenstein E, Vazquez-Roque R et al. Cerebrolysin Modulates Pronerve Growth Factor/Nerve Growth Factor Ratio and Ameliorates the Cholinergic Deficit in a Transgenic Model of Alzheimer’s Disease. J Neurosci Res 2013; 91: 167–77.
45. Hampson DR, Windisch M, Baskys A. Increased binding of BDNF to TrkB induced by the antidemetia drug Cerebrolysin. Soc Neurosci 1997; 23: 1896.
46. Ma DK, Bonaguidi MA, Ming GL, Song H. Adult neural stem cells in the mammalian central nervous system. Cell Res 2009; 19: 672–82.
47. Rockenstein E et al. Effects of Cerebrolysin on neurogenesis in an APP transgenic model of Alzheimer’s disease. Acta Neuropathol 2007; 113: 265–83.
48. Zhang Y et al. Improvement in functional recovery with administration of Cerebrolysin after experimental closed head injury. J Neurosug 2013; 118: 1343–55.
49. Zhang C, Chopp M et al. Cerebrolysin Enhances Neurogenesis in the Ischemic Brain and Improves Functional Outcome After Stroke. J Neurosci Res 2010; 88: 3275–81.
50. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116: 85–97.
________________________________________________
1. World Population Ageing. United Nations publication 2009; Sales No. E.10.XIII.5
2. Prakticheskie rekomendatsii. Vedenie zhenshchin v peri- i postmenopauze. Moskva 2010. Pod red. V.P.Smetnik, L.M.Il'ina. Iaroslavl': Litera, 2010; s. 222. [in Russian]
3. Chazova I.E., Smetnik V.P., Balan V.E. i dr. Vedenie zhenshchin s serdechno-sosudistym riskom v peri- i postmenopauze: konsensus rossiiskikh kardiologov i ginekologov. Problemy reproduktsii. 2008; 5: 79–87. [in Russian]
4. Salomon JA, Wang H, Freeman MK et al. Healthy life expectancy for 187 countries, 1990–2010: a systematic analysis for the Global Burden Disease Study 2010. The Lancet 2012; 380: 2144–62.
5. Masson M, Siniawski D, Krauss J, Cagide A. Clinical Applicability of the Framingham 30-Year Risk Score. Usefulness in Cardiovascular Risk Stratification and the Diagnosis of Carotid Atherosclerotic Plaqu. Rev Esp Cardiol 2011; 64 (4): 305–11.
6. Sturdee DW, Pines A on behalf of the International Menopause Society Writing Group. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 2011; 14: 302–20.
7. Physicians’ perception of guideline-recommended low-density lipoprotein target values: characteristics of misclassified patients). European Heart J 2010. doi: 10.1093/eurheartj/ehq026
8. Brown S, Rosen CJ. Osteoporosis. Med Clin North Am 2003; 87: 1039–63.
9. Roussow JE, Anderson GL, Prentice RL et al. Writing group for the women\'s health initiative investigators. Risks and benefits of estrogen + progestin in healthy postmenopausal women. JAMA 2002; 288: 321–33.
10. Osteoporoz. Diagnostika, profilaktika i lechenie. Klinicheskie rekomendatsii. Pod red. L.I.Benevolenskoi, O.M.Lesniak. M.: GEOTAR-Media, 2010. [in Russian]
11. Birns J, Morris R, Donaldson N, Kalra L. The effects of blood pressure reduction on cognitive function: a review of effects based on pooled data from clinical trials. J Hypertens 2006; 24: 1907–14.
12. Birns J, Kalra L. Cognitive function and hypertension. Human Hypertension 2009; 23: 86–96.
13. O’Brien JT, Erkinjuntti T, Reisberg B et al. Vascular cognitive impairment. Lancet Neurology 2003; 2: 89–98.
14. Shtul'man D.R., Levin O.S. Nevrologiia. Spravochnik prakticheskogo vracha. M.: Medpress-inform, 2008. [in Russian]
15. Trojano L, Incalzi RA, Acaforo D et al. Cognitive Impairment: a key feature of congestive heart failure in the elderly. J Neurol 2003; 250: 1456–63.
16. Jefferson A, Benjamin E. Cardiovascular disease, cognitive decline and dementia. Vascular cognitive impairment in clinical practice. Eds. L.Wahlung, T.Erkinjuntti, S.Gauthier. Cambridge, 2009; p. 166–77.
17. Cacciatore F, Abete P, Ferrara N et al. Congestive heartfailure and cognitive impairment in an older population. Am Geriatr Soc 1998; 46: 1343–8.
18. Pullicino PM, Hart J. Cognitive Impairment in congestive heart failure. Neurology 2001; 57: 1945–6.
19. Gorkin L, Norvell NK, Rosen RC et al. Assessment of quality of life as observed from the baseline data of the studies of left ventricular dysfunction (SOLVD) trial quality of life substudy. Am J Cardiol 1993; 71: 1069–73.
20. Georgiadis D, Sievert M, Cencetti S et al. Cerebrovascular reactivity is impaired in patients with cardiac failure. Eur Heart J 2000; 21: 407–13.
21. Zakharov V.V., Iakhno N.N. Kognitivnye rasstroistva v pozhilom i starcheskom vozraste. Metodicheskoe posobie dlia vrachei. M., 2005. [in Russian]
22. Suslina Z.A., Varakin Iu.Ia., Vereshchagin N.V. Sosudistye zabolevaniia golovnogo mozga. Epidemiologiia. Osnovy profilaktiki. M.: MEDpress-inform, 2009. [in Russian]
23. Damulin I.V. Bolezn' Al'tsgeimera i sosudistaia dementsiia. Pod red. N.N.Iakhno. M., 2002; s. 85. [in Russian]
24. Insul't. Rukovodstvo. Pod red. L.V.Stakhovskoi, S.V.Kotova. M.: MIA, 2014. [in Russian]
25. Gomazkov O.A. Neirotroficheskie i rostovye faktory mozga: reguliatornaia spetsifika i terapevticheskii potentsial. Uspekhi fiziolog. nauk. 2005; 36 (2): 1–25. [in Russian]
26. Gusev E.I., Bogolepova A.N. Kognitivnye narusheniia pri tserebrovaskuliarnykh zabolevaniiakh. M.: MEDprecs-inform, 2013. [in Russian]
27. Gusev E.I., Skvortsova V.I. Ishemiia golovnogo mozga. M.: Meditsina, 2001. [in Russian]
28. Heiss WD et al. Cerebrolysin in Patients with acute Ischemic Stroke in Asia results of a double-blind, placebo controlled randomized trial. Stroke 2012; 43 (3): 631–6.
29. Gusev E.I., Gekht A.B. i dr. Klinicheskie i farmakoekonomicheskie osobennosti primeneniia Tserebrolizina v vosstanovitel'nom lechenii ishemicheskogo insul'ta. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2007; 107 (10): 26–33. [in Russian]
30. Guekht AB, Moessler H, Novak PH, Gusev EI. Cerebrolysin in Vascular Dementia: Improvement of Clinical Outcome in a Randomized, Double-Blind, Placebo-Controlled Multicenter Trial. J Stroke Cerebrovasc Dis 2010; p. 1–9. [in Russian]
31. Chen N et al. Cerebrolysin for vascular dementia (Review), The Cochrane Collaboration, 2013.
32. Wei Z, He Q, Wang B, Chen H. Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer’s disease, J Neural Transm 2007; 114 (5 Suppl.): 629–34.
33. Alvarez XA, Sampedro C, Figueroa J et al. Reductions in qEEG slowing over one year and after treatment with Cerebrolysin in patients with moderate-sever traumatic brain injury. J Neural Transm 2008; 115 (Suppl.): 683–92.
34. Wang M et al. The effect observation of head injury treated with Cerebrolysin. J Xi’an Med University 1998; 19 (4).
35. Kalyn Ia.B., Safarova T.P. i dr. Sravnitel'naia effektivnost' i bezopasnost' antidepressivnoi mono- i mul'timodal'noi terapii u pozhilykh bol'nykh depressiei. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova.2014; 114 (6): 20–9. [in Russian]
36. Chen H et al. Trophic factors counteract elevated FGF-2-induced inhibition of adult neurogenesis. Neurobiol Aging 2007; 28 (8): 1148–62.
37. Gromova O.A., Torshin I.Iu., Gogoleva I.V. Mekhanizmy neirotroficheskogo i neiroprotektornogo deistviia preparata tserebrolizin pri ishemii golovnogo mozga. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2014; 3 (Vyp. 2): 43–50. [in Russian]
38. Gromova O.A., Tret'iakov V.E., Moshkovskii S.A. i dr. Oligipeptidnaia membrannaia fraktsiia tserebrolizina (perevod). Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2006; 106 (7): 68–70. [in Russian]
39. Gromova O.A. i dr. Molekuliarnye mekhanizmy vozdeistviia aminokislot v sostave Tserebrolizina na neirotransmissiiu. Neirotroficheskie i neiroprotektivnye effekty aminokislot. Trudnyi patsient. 2010; 8 (4): 25–31. [in Russian]
40. Gromova O.A., Kudrin A.V. Novye grani molekuliarnoi farmakologii neirotrofikov prirodnogo proiskhozhdeniia. Mikroelementy kak komponent neiroprotektornykh ligandov (obzor). Mezhdunar. med. zhurn. 2001; 4: 441–5. [in Russian]
41. Gromova O.A., Krasnykh L.M., Gusev E.I., Nikonov A.A., Vitaminnaia aktivnost' tserebrolizina. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2005; 5: 59–61. [in Russian]
42. Muresanu DF, Buzoianu A, Florian SI, von Wild T. Towards a roadmap in brain protection and recovery. J Cell Mol Med 2012; 16 (12): 2861–71.
43. Masliah E, Díez-Tejedor E. The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs Today (Barc) 2012; 48 (Suppl. A): 3–24. doi: 10.1358/dot.2012.48(Suppl.A).1739716.
44. Ubhi K, Rockenstein E, Vazquez-Roque R et al. Cerebrolysin Modulates Pronerve Growth Factor/Nerve Growth Factor Ratio and Ameliorates the Cholinergic Deficit in a Transgenic Model of Alzheimer’s Disease. J Neurosci Res 2013; 91: 167–77.
45. Hampson DR, Windisch M, Baskys A. Increased binding of BDNF to TrkB induced by the antidemetia drug Cerebrolysin. Soc Neurosci 1997; 23: 1896.
46. Ma DK, Bonaguidi MA, Ming GL, Song H. Adult neural stem cells in the mammalian central nervous system. Cell Res 2009; 19: 672–82.
47. Rockenstein E et al. Effects of Cerebrolysin on neurogenesis in an APP transgenic model of Alzheimer’s disease. Acta Neuropathol 2007; 113: 265–83.
48. Zhang Y et al. Improvement in functional recovery with administration of Cerebrolysin after experimental closed head injury. J Neurosug 2013; 118: 1343–55.
49. Zhang C, Chopp M et al. Cerebrolysin Enhances Neurogenesis in the Ischemic Brain and Improves Functional Outcome After Stroke. J Neurosci Res 2010; 88: 3275–81.
50. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116: 85–97.
Авторы
В.Н.Шишкова
ГБУЗ Центр патологии речи и нейрореабилитации. 109240, Россия, Москва, ул. Николоямская, д. 20 Veronika-1306@mail.ru
________________________________________________
V.N.Shishkova
Center for Speech Pathology and Neurorehabilitation. 109240, Russian Federation, Moscow, ul. Nikoloyamskaia, d. 20 Veronika-1306@mail.ru